TISIDB

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF00036 EF hand PF01023 S-100/ICaBP type calcium binding domain
Function	Probably acts as a Ca(2+) signal transducer (PubMed:22399290). In response to an increase in intracellular Ca(2+) levels, binds calcium which triggers a conformational change (PubMed:23351007). This conformational change allows interaction of S1001A with specific target proteins, such as TPR-containing proteins, and the modulation of their activity (PubMed:22399290).

> Gene Ontology [ TOP ]
Biological Process	GO:0003013 circulatory system process GO:0003015 heart process GO:0006816 calcium ion transport GO:0008015 blood circulation GO:0008016 regulation of heart contraction GO:0010959 regulation of metal ion transport GO:0021762 substantia nigra development GO:0022898 regulation of transmembrane transporter activity GO:0030901 midbrain development GO:0032409 regulation of transporter activity GO:0032411 positive regulation of transporter activity GO:0032412 regulation of ion transmembrane transporter activity GO:0032414 positive regulation of ion transmembrane transporter activity GO:0034762 regulation of transmembrane transport GO:0034764 positive regulation of transmembrane transport GO:0034765 regulation of ion transmembrane transport GO:0034767 positive regulation of ion transmembrane transport GO:0043270 positive regulation of ion transport GO:0044057 regulation of system process GO:0048857 neural nucleus development GO:0051924 regulation of calcium ion transport GO:0051928 positive regulation of calcium ion transport GO:0060047 heart contraction GO:0070588 calcium ion transmembrane transport GO:0070838 divalent metal ion transport GO:0072511 divalent inorganic cation transport GO:1901019 regulation of calcium ion transmembrane transporter activity GO:1901021 positive regulation of calcium ion transmembrane transporter activity GO:1901385 regulation of voltage-gated calcium channel activity GO:1901387 positive regulation of voltage-gated calcium channel activity GO:1903169 regulation of calcium ion transmembrane transport GO:1903522 regulation of blood circulation GO:1904062 regulation of cation transmembrane transport GO:1904064 positive regulation of cation transmembrane transport GO:1904427 positive regulation of calcium ion transmembrane transport GO:2001257 regulation of cation channel activity GO:2001259 positive regulation of cation channel activity
Molecular Function	GO:0044548 S100 protein binding GO:0048306 calcium-dependent protein binding GO:0051117 ATPase binding
Cellular Component	GO:0016528 sarcoplasm GO:0016529 sarcoplasmic reticulum GO:0030016 myofibril GO:0030017 sarcomere GO:0030018 Z disc GO:0031430 M band GO:0031672 A band GO:0031674 I band GO:0043292 contractile fiber GO:0044449 contractile fiber part

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-5686938: Regulation of TLR by endogenous ligand R-HSA-168898: Toll-Like Receptors Cascades

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between S100A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between S100A1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
16899613	Bladder carcinoma	Promote immunity	Immunohistochemical staining for HLA class I, CD4, CD8, CD20, CD68, TIA-1, S-100, and FOXP3 was carried out on specimens from 30 patients who underwent BCG immunotherapy from whom both pretreatment and posttreatment specimens were obtained. Our data show that expression of HLA class I molecules on tumor cells contributes significantly to the therapeutic effect of BCG immunotherapy for bladder cancer. It is suggested that CTLs may be one of main effectors in this therapy.

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of S100A1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of S100A1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	1.012	0.337
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.434	0.926
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	2.087	0.514
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.641	0.327
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.07	0.961
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1.358	0.411
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.141	0.833
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.543	0.794
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.793	0.744
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.788	0.757
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-2.382	0.546
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.534	0.0438

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of S100A1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of S100A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of S100A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by S100A1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of S100A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of S100A1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between S100A1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	S100A1
Name	S100 calcium binding protein A1
Aliases	S100-alpha; S100A; S100 calcium-binding protein A1; S-100 protein alpha chain; S-100 protein subunit alpha; ......
Chromosomal Location	1q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting S100A1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting S100A1.

ID	Name	Drug Type	Targets	#Targets
DB00768	Olopatadine	Small Molecule	HRH1, S100A1, S100A12, S100A13, S100A2, S100B	6

Browse S100A1